Maximizing ROI: Five Key Ways Sponsors And CROs Can Optimize Ophthalmic Clinical Trials

Ophthalmic clinical trials are integral to advancing treatments for vision-threatening conditions, but their inherent complexity presents challenges. Delays in recruitment, data variability, and site management issues can derail timelines and inflate costs. To mitigate these risks, sponsors and CROs can adopt innovative strategies like point-of-need assessments, which bring ophthalmic services directly to patients. These solutions reduce recruitment barriers, enhance retention, and expand access to diverse populations by eliminating logistical hurdles such as travel and scheduling conflicts.
This patient-centric approach not only accelerates timelines but also improves trial inclusivity, ensuring regulatory and ethical standards are met. High-quality data and compliance are achieved through partnerships that minimize protocol deviations and ensure consistent, reliable data collection, expediting regulatory review. Additionally, scalable and flexible solutions address site burden and adapt to dynamic trial needs, helping sponsors maintain budget and schedule integrity. By embracing point-of-need models and strategic collaborations, sponsors and CROs can streamline ophthalmic trials, enhance efficiency, and maximize ROI while advancing sight-saving therapies.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.